Stock Ratings / Health Care / NNNN / forecast

TKNO (44) MYGN (39) ACHV (44) QDEL (30) ⌘ Pro Terminal →

Anbio Biotechnology (Class A) (NNNN) 12-Month Stock Forecast & Price Target Cone

Q: What is NNNN's 12-month stock price target?

Anbio Biotechnology (Class A) (NNNN) carries a 12-month consensus base price target of $3.5 (-5.9% from $3.72), with a bull-case target of $46.97 and a bear-case floor of $2.73.

Q: Is NNNN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NNNN D (Sell — SELL) with an RQD Confidence score of 45/100.

$3.72 -3.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Anbio Biotechnology (Class A) (NNNN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $535.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NNNN)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NNNN Position Size: $10,000

Shares at $3.72: 2688.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.73

$7,339

$-2,661 (-26.6%)

12M Consensus BaseTarget $3.50

$9,409

$-591 (-5.9%)

12M Bull Case BreakoutTarget $46.97

$126,263

+$116,263 (+1162.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$44	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNNN)

✓Walkthrough of NNNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NNNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -86.95%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.75H $3.75L $3.33C $3.72VOL 39.0K

RES: $7.62SUP: $2.07SMA50: $5.47SMA200: $17.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NNNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NNNN Butterfly Map → + Track NNNN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +5.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NNNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NNNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NNNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNNN)

Health Care Rank #479 of 1016 ⚔️ TKNO vs NNNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NNNN vs. TKNO, MYGN, ACHV, QDEL)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Anbio Biotechnology (Class A) (NNNN) ranks #479 by composite RQD confidence (45/100, grade D) and #436 by equity capitalization ($535.3M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NNNN ACTIVE Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	Benchmark Subject
TKNO Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-nnnn →
MYGN Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	/mygn-vs-nnnn →
ACHV Achieve Life Sciences Inc.	D	44/100	—	—	-35.0%	+4.96%	$739.9M	/achv-vs-nnnn →
QDEL QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-nnnn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001982708

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anbio Biotechnology (Class A) (NNNN) reported GAAP revenue of $8.6M (+5.6% vs. FY2024 revenue of $8.2M , and +28.8% cumulative change since FY2023) , GAAP net income of $6.4M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (-423.9% YoY). On the balance sheet, NNNN closed FY2025 with $30.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$8.6M	$6.4M	-$6.7M	-$6.7M	$30.2M	—
FY2024 (FY)	2024-12-31	$8.2M	$2.4M	$2.1M	$2.1M	$18.9M	—
FY2023 (FY)	2023-12-31	$6.7M	$2.3M	$898.4K	$898.4K	—	—

3. NNNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Anbio Biotechnology (Class A) (NASDAQ: NNNN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $3.72 (-3.12% 1D, market cap $535.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NNNN ranks #479 in composite RQD confidence.

How does NNNN compare to TKNO and MYGN in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NNNN carries a Roarable D (45/100 RQD), trailing P/E of 83.6x, gross margin of 87.2%, and ROIC of 17.0%. By comparison, TKNO (Alpha Teknova Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M) and MYGN (Myriad Genetics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NNNN?

Per NNNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001982708), Anbio Biotechnology (Class A) generated $8.6M in revenue (+5.6% YoY), $6.4M in net income, and -$6.7M in free cash flow against $30.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NNNN trading relative to its 50-day, 200-day, and 52-week technical levels?

NNNN last traded at $3.72 (-3.12% on volume of 41,343 shares), positioning the stock -31.99% below its 50-day simple moving average ($5.47) and -78.53% below its 200-day simple moving average ($17.33). Across its 52-week range of $3.09 to $44.73, NNNN sits at the 1.5% percentile with a 14-day RSI of 29.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.25 to $4.19).

NNNN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NNNN's 12-month stock price target?

Anbio Biotechnology (Class A) (NNNN) carries a 12-month consensus base price target of $3.5 (-5.9% from $3.72), with a bull-case target of $46.97 and a bear-case floor of $2.73.

Is NNNN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NNNN D (Sell — SELL) with an RQD Confidence score of 45/100.

Direct Sub-Reports: NNNN RQD Cockpit NNNN 12M Forecast NNNN Earnings & Move NNNN Dividends & DRIP NNNN Insiders & 13F NNNN Whale Options NNNN Profit Sankey NNNN News & Why